# Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts

Study · id `cardio:ct-nct05369975` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05369975](<https://clinicaltrials.gov/study/NCT05369975>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05369975

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 113 participants.

## Technical summary

Registry record NCT05369975. Non-randomized; no masking; primary purpose treatment. Start 2022-04-19 (actual); primary completion 2026-04-21 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 113 participants (enrolled count; ClinicalTrials.gov record NCT05369975, source copy `cardio:ctgov-nct05369975-2026-05-05`, retrieved 2026-10-26)
- Started: 2022-04-19 (actual) (ClinicalTrials.gov record NCT05369975, source copy `cardio:ctgov-nct05369975-2026-05-05`, retrieved 2026-10-26)
- Primary completion: 2026-04-21 (actual) (ClinicalTrials.gov record NCT05369975, source copy `cardio:ctgov-nct05369975-2026-05-05`, retrieved 2026-10-26)
- Completion: 2026-04-21 (actual) (ClinicalTrials.gov record NCT05369975, source copy `cardio:ctgov-nct05369975-2026-05-05`, retrieved 2026-10-26)
- Countries: Austria; Belgium; Czechia; France; Germany; Italy; Netherlands; Slovenia; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT05369975, source copy `cardio:ctgov-nct05369975-2026-05-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05369975-2026-05-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
- Acronym: PAES
- Condition: Kidney Transplantation in Highly Sensitized Patients
- Intervention (Drug): Imlifidase
- Intervention (Other): Normal Transplantation Routine
- Lead sponsor: Hansa Biopharma AB
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 1b3d6b465226546b122bf1c1ff3da1c0b9b555861651e93adb44df16203f7018
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
